NZ507728A - Information from a cDNA library created from keratinocytes, dermal papilla, neonatal foreskin fibroblast or embryonic skin cells is used to treating cancer, angiogenesis, skin inflammation, inflammatory diseases or stimulating keratinocyte growth - Google Patents

Information from a cDNA library created from keratinocytes, dermal papilla, neonatal foreskin fibroblast or embryonic skin cells is used to treating cancer, angiogenesis, skin inflammation, inflammatory diseases or stimulating keratinocyte growth

Info

Publication number: NZ507728A
Authority: NZ; New Zealand
Prior art keywords: seq; sequences; polypeptide; sequence; amino acid
Prior art date: 1998-04-29

Application number

NZ507728A

Other languages

English (en)

Inventor

Lorna Strachan

Matthew Sleeman

James Douglas Watson

Rene Onrust

Anand Kumble

James Greg Murison

Original Assignee

Genesis Res & Dev Corp Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-29

Filing date

1999-04-29

Publication date

2002-06-28

1998-11-09 Priority claimed from US09/188,930 external-priority patent/US6150502A/en

1999-04-29 Application filed by Genesis Res & Dev Corp Ltd filed Critical Genesis Res & Dev Corp Ltd

2002-06-28 Publication of NZ507728A publication Critical patent/NZ507728A/en

Links

230000012010 growth Effects 0.000 title claims abstract description 42
210000002510 keratinocyte Anatomy 0.000 title claims abstract description 39
206010028980 Neoplasm Diseases 0.000 title claims abstract description 36
230000033115 angiogenesis Effects 0.000 title claims abstract description 11
201000011510 cancer Diseases 0.000 title claims abstract description 10
230000004936 stimulating effect Effects 0.000 title claims abstract description 9
201000004624 Dermatitis Diseases 0.000 title claims abstract description 6
210000004927 skin cell Anatomy 0.000 title abstract description 16
208000027866 inflammatory disease Diseases 0.000 title abstract description 6
239000002299 complementary DNA Substances 0.000 title description 59
230000002500 effect on skin Effects 0.000 title description 8
210000002950 fibroblast Anatomy 0.000 title description 8
210000003953 foreskin Anatomy 0.000 title description 6
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 167
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 166
229920001184 polypeptide Polymers 0.000 claims abstract description 165
210000004027 cell Anatomy 0.000 claims abstract description 136
102000040430 polynucleotide Human genes 0.000 claims abstract description 88
108091033319 polynucleotide Proteins 0.000 claims abstract description 88
239000002157 polynucleotide Substances 0.000 claims abstract description 88
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
239000013604 expression vector Substances 0.000 claims abstract description 14
201000010099 disease Diseases 0.000 claims abstract description 8
125000003275 alpha amino acid group Chemical group 0.000 claims description 40
239000000203 mixture Substances 0.000 claims description 32
239000002253 acid Substances 0.000 claims description 22
239000002773 nucleotide Substances 0.000 claims description 22
125000003729 nucleotide group Chemical group 0.000 claims description 22
108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 17
230000002441 reversible effect Effects 0.000 claims description 15
150000001413 amino acids Chemical class 0.000 claims description 12
239000002671 adjuvant Substances 0.000 claims description 9
210000002919 epithelial cell Anatomy 0.000 claims description 9
230000002401 inhibitory effect Effects 0.000 claims description 8
230000015788 innate immune response Effects 0.000 claims description 6
210000000265 leukocyte Anatomy 0.000 claims description 6
239000000969 carrier Substances 0.000 claims description 5
230000004899 motility Effects 0.000 claims description 5
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
239000003623 enhancer Substances 0.000 claims 5
208000012902 Nervous system disease Diseases 0.000 claims 2
208000025966 Neurological disease Diseases 0.000 claims 2
230000005907 cancer growth Effects 0.000 claims 2
238000012827 research and development Methods 0.000 claims 1
239000003643 water by type Substances 0.000 claims 1
238000000034 method Methods 0.000 abstract description 32
108090000623 proteins and genes Proteins 0.000 description 74
102000004169 proteins and genes Human genes 0.000 description 61
235000018102 proteins Nutrition 0.000 description 59
235000011468 Albizia julibrissin Nutrition 0.000 description 41
241001070944 Mimosa Species 0.000 description 41
108020004999 messenger RNA Proteins 0.000 description 34
230000014509 gene expression Effects 0.000 description 31
108020004414 DNA Proteins 0.000 description 24
210000003491 skin Anatomy 0.000 description 24
210000001519 tissue Anatomy 0.000 description 22
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
239000002953 phosphate buffered saline Substances 0.000 description 20
241000699670 Mus sp. Species 0.000 description 18
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 18
238000005516 engineering process Methods 0.000 description 17
102000005962 receptors Human genes 0.000 description 16
108020003175 receptors Proteins 0.000 description 16
238000011282 treatment Methods 0.000 description 16
101800003838 Epidermal growth factor Proteins 0.000 description 15
102400001368 Epidermal growth factor Human genes 0.000 description 15
229940116977 epidermal growth factor Drugs 0.000 description 15
238000003556 assay Methods 0.000 description 14
210000000130 stem cell Anatomy 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
239000000872 buffer Substances 0.000 description 12
239000000523 sample Substances 0.000 description 12
102000001301 EGF receptor Human genes 0.000 description 11
108060006698 EGF receptor Proteins 0.000 description 11
108700025832 Serum Response Element Proteins 0.000 description 11
238000004458 analytical method Methods 0.000 description 11
230000001580 bacterial effect Effects 0.000 description 11
239000013642 negative control Substances 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
238000002955 isolation Methods 0.000 description 10
150000007523 nucleic acids Chemical class 0.000 description 10
239000008188 pellet Substances 0.000 description 10
150000007513 acids Chemical class 0.000 description 9
230000004069 differentiation Effects 0.000 description 9
230000006870 function Effects 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
239000012528 membrane Substances 0.000 description 9
101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 8
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 8
102100025304 Integrin beta-1 Human genes 0.000 description 8
108091054455 MAP kinase family Proteins 0.000 description 8
102000043136 MAP kinase family Human genes 0.000 description 8
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 8
230000010261 cell growth Effects 0.000 description 8
238000012512 characterization method Methods 0.000 description 8
239000003814 drug Substances 0.000 description 8
210000004209 hair Anatomy 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
239000003446 ligand Substances 0.000 description 8
239000008194 pharmaceutical composition Substances 0.000 description 8
238000003752 polymerase chain reaction Methods 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
230000000694 effects Effects 0.000 description 7
210000002615 epidermis Anatomy 0.000 description 7
239000012139 lysis buffer Substances 0.000 description 7
230000005012 migration Effects 0.000 description 7
238000013508 migration Methods 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
229960005486 vaccine Drugs 0.000 description 7
230000029663 wound healing Effects 0.000 description 7
102000019034 Chemokines Human genes 0.000 description 6
108010012236 Chemokines Proteins 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
108091060211 Expressed sequence tag Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
238000000636 Northern blotting Methods 0.000 description 6
101150109894 TGFA gene Proteins 0.000 description 6
206010052428 Wound Diseases 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 6
230000000692 anti-sense effect Effects 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
230000012292 cell migration Effects 0.000 description 6
210000004207 dermis Anatomy 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
210000002490 intestinal epithelial cell Anatomy 0.000 description 6
239000013641 positive control Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
230000004044 response Effects 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
241001529936 Murinae Species 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
230000004913 activation Effects 0.000 description 5
238000001994 activation Methods 0.000 description 5
230000024245 cell differentiation Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000003399 chemotactic effect Effects 0.000 description 5
PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 5
239000012634 fragment Substances 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
210000002216 heart Anatomy 0.000 description 5
210000003000 inclusion body Anatomy 0.000 description 5
230000006698 induction Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
230000026731 phosphorylation Effects 0.000 description 5
238000006366 phosphorylation reaction Methods 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000019254 respiratory burst Effects 0.000 description 5
238000012216 screening Methods 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
210000004988 splenocyte Anatomy 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 4
201000004384 Alopecia Diseases 0.000 description 4
108010062580 Concanavalin A Proteins 0.000 description 4
101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 4
101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 4
101000655540 Homo sapiens Protransforming growth factor alpha Proteins 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
102000019149 MAP kinase activity proteins Human genes 0.000 description 4
108040008097 MAP kinase activity proteins Proteins 0.000 description 4
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 4
108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 4
101800004564 Transforming growth factor alpha Proteins 0.000 description 4
239000000556 agonist Substances 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
238000009826 distribution Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000000975 dye Substances 0.000 description 4
235000013861 fat-free Nutrition 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
230000004927 fusion Effects 0.000 description 4
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
210000003780 hair follicle Anatomy 0.000 description 4
230000003676 hair loss Effects 0.000 description 4
230000035876 healing Effects 0.000 description 4
102000043392 human TGFA Human genes 0.000 description 4
230000028993 immune response Effects 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
210000000936 intestine Anatomy 0.000 description 4
238000002372 labelling Methods 0.000 description 4
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
235000013336 milk Nutrition 0.000 description 4
239000008267 milk Substances 0.000 description 4
210000004080 milk Anatomy 0.000 description 4
210000001672 ovary Anatomy 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
210000002826 placenta Anatomy 0.000 description 4
230000008569 process Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
210000001541 thymus gland Anatomy 0.000 description 4
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
208000011231 Crohn disease Diseases 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
108091034057 RNA (poly(A)) Proteins 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000002683 foot Anatomy 0.000 description 3
238000012165 high-throughput sequencing Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000004020 luminiscence type Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000006166 lysate Substances 0.000 description 3
238000010841 mRNA extraction Methods 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000004005 microsphere Substances 0.000 description 3
UXDAWVUDZLBBAM-UHFFFAOYSA-N n,n-diethylbenzeneacetamide Chemical compound CCN(CC)C(=O)CC1=CC=CC=C1 UXDAWVUDZLBBAM-UHFFFAOYSA-N 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
238000011580 nude mouse model Methods 0.000 description 3
230000017363 positive regulation of growth Effects 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000007858 starting material Substances 0.000 description 3
210000002536 stromal cell Anatomy 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 2
208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
108050006947 CXC Chemokine Proteins 0.000 description 2
102000019388 CXC chemokine Human genes 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
102000016918 Complement C3 Human genes 0.000 description 2
108010028780 Complement C3 Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108050001049 Extracellular proteins Proteins 0.000 description 2
102100037362 Fibronectin Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000021164 cell adhesion Effects 0.000 description 2
230000006369 cell cycle progression Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
201000006662 cervical adenocarcinoma Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
102000003675 cytokine receptors Human genes 0.000 description 2
108010057085 cytokine receptors Proteins 0.000 description 2
230000034994 death Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000001823 molecular biology technique Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
210000000066 myeloid cell Anatomy 0.000 description 2
AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 2
201000011682 nervous system cancer Diseases 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000000059 patterning Methods 0.000 description 2
229940056360 penicillin g Drugs 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
229940054269 sodium pyruvate Drugs 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
239000013598 vector Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
101150072531 10 gene Proteins 0.000 description 1
PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 description 1
GTACSIONMHMRPD-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethylsulfanyl]-2,6-difluorophenoxy]acetamide Chemical compound C1=C(F)C(OCC(=O)N)=C(F)C=C1SCCNS(=O)(=O)C1=CC=CC=C1 GTACSIONMHMRPD-UHFFFAOYSA-N 0.000 description 1
GDTHVMAIBQVUMV-UHFFFAOYSA-N 2-oxopentanal Chemical compound CCCC(=O)C=O GDTHVMAIBQVUMV-UHFFFAOYSA-N 0.000 description 1
108010049777 Ankyrins Proteins 0.000 description 1
102000008102 Ankyrins Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
101710130081 Aspergillopepsin-1 Proteins 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101800003265 Beta-thromboglobulin Proteins 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241001227713 Chiron Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000009268 Collagen Receptors Human genes 0.000 description 1
108010048623 Collagen Receptors Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108050001718 Death domains Proteins 0.000 description 1
102000010170 Death domains Human genes 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 1
102000012545 EGF-like domains Human genes 0.000 description 1
108050002150 EGF-like domains Proteins 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102000002090 Fibronectin type III Human genes 0.000 description 1
108050009401 Fibronectin type III Proteins 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
101000605827 Homo sapiens Pinin Proteins 0.000 description 1
101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108700002232 Immediate-Early Genes Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102100025323 Integrin alpha-1 Human genes 0.000 description 1
108010041341 Integrin alpha1 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
101000880099 Mus musculus Sushi-repeat-containing protein SRPX Proteins 0.000 description 1
101100098966 Mus musculus Ticam2 gene Proteins 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
102000005823 Nucleotide-sugar transporter Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
102100038374 Pinin Human genes 0.000 description 1
102100036154 Platelet basic protein Human genes 0.000 description 1
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
241001068263 Replication competent viruses Species 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
206010072170 Skin wound Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
238000009468 active modified atmosphere packaging Methods 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000000964 angiostatic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
108010054176 apotransferrin Proteins 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
208000037896 autoimmune cutaneous disease Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000003995 blood forming stem cell Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
238000010366 cell biology technique Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000021617 central nervous system development Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
229960002222 dihydrostreptomycin Drugs 0.000 description 1
229960001162 dihydrostreptomycin sulfate Drugs 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
229960004279 formaldehyde Drugs 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
102000052781 human TNFRSF11B Human genes 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
210000001985 kidney epithelial cell Anatomy 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
238000012775 microarray technology Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
108020003699 nucleotide-sugar transporter Proteins 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
239000000049 pigment Substances 0.000 description 1
210000005059 placental tissue Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000004853 protein function Effects 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000026267 regulation of growth Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000003571 reporter gene assay Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000001022 rhodamine dye Substances 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
108010065275 type 1 taste receptors Proteins 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
230000006459 vascular development Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Cell Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NZ507728A 1998-04-29 1999-04-29 Information from a cDNA library created from keratinocytes, dermal papilla, neonatal foreskin fibroblast or embryonic skin cells is used to treating cancer, angiogenesis, skin inflammation, inflammatory diseases or stimulating keratinocyte growth NZ507728A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US6972698A	1998-04-29	1998-04-29
US09/188,930 US6150502A (en)	1998-04-29	1998-11-09	Polypeptides expressed in skin cells
PCT/NZ1999/000051 WO1999055865A1 (en)	1998-04-29	1999-04-29	Polynucleotides isolated from skin cells and methods for their use

Publications (1)

Publication Number	Publication Date
NZ507728A true NZ507728A (en)	2002-06-28

Family

ID=22090833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ507728A NZ507728A (en)	1998-04-29	1999-04-29	Information from a cDNA library created from keratinocytes, dermal papilla, neonatal foreskin fibroblast or embryonic skin cells is used to treating cancer, angiogenesis, skin inflammation, inflammatory diseases or stimulating keratinocyte growth

Country Status (7)

Country	Link
EP (1)	EP1073740A4 (ja)
JP (1)	JP2002512798A (ja)
CN (1)	CN1158386C (ja)
AU (1)	AU758074B2 (ja)
CA (1)	CA2327317A1 (ja)
NZ (1)	NZ507728A (ja)
WO (1)	WO1999055865A1 (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7435793B2 (en) *	1998-05-15	2008-10-14	Genentech, Inc.	Peptides that induce chondrocyte redifferentiation
AU8921698A (en)	1997-08-29	1999-03-16	Human Genome Sciences, Inc.	Follistatin-3
US6953662B2 (en)	1997-08-29	2005-10-11	Human Genome Sciences, Inc.	Follistatin-3
EP1205489B1 (en) *	1997-11-21	2006-07-05	Genentech, Inc.	Polypeptide and nucleic acids encoding the same
US6573095B1 (en)	1998-04-29	2003-06-03	Genesis Research & Development Corporation Limited	Polynucleotides isolated from skin cells
US7771719B1 (en) *	2000-01-11	2010-08-10	Genentech, Inc.	Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7125959B2 (en)	1998-05-15	2006-10-24	Genentech, Inc.	PRO4405 polypeptides
EP1088079A2 (en) *	1998-06-16	2001-04-04	Sugen, Inc.	Nek-related and bub1-related protein kinases
EP1783140A3 (en) *	1998-10-16	2007-07-11	Otsuka Pharmaceutical Co., Ltd.	Neovascular-specific peptides
US7294482B2 (en)	1998-11-19	2007-11-13	Millennium Pharmaceuticals, Inc.	EGF-like nucleic acids
AU2153500A (en) *	1998-11-19	2000-06-05	Millennium Pharmaceuticals, Inc.	Egf-like nucleic acids and polypeptides and uses thereof
US6544946B1 (en)	1999-02-19	2003-04-08	Zymogenetics, Inc.	Inhibitors for use in hemostasis and immune function
KR20010102130A (ko)	1999-02-19	2001-11-15	리스 데브라 케이.	지혈 및 면역기능에 사용하기 위한 억제제
DK1616878T3 (da) *	1999-03-23	2009-03-30	Genentech Inc	Udskilte og membranspændende polypeptider samt nukleinsyrer kodende for disse
US6620909B1 (en)	1999-04-20	2003-09-16	Zymogenetics, Inc.	Adipocyte complement related protein homolog zacrp2
JP2002541846A (ja) *	1999-04-20	2002-12-10	ザイモジェネティクス，インコーポレイティド	脂肪細胞補体関連タンパク質同族体ｚａｃｒｐ２
EP1173483A4 (en) *	1999-04-28	2002-07-10	Smithkline Beecham Corp	ACRP30R1M, APPROVED BY ACRP30
US7034132B2 (en)	2001-06-04	2006-04-25	Anderson David W	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1203816A4 (en) *	1999-07-08	2004-12-08	Fujisawa Pharmaceutical Co	FACTOR REGULATING AGGLUTINATION OF BETA-AMYLOID PROTEIN
US6960435B1 (en)	1999-07-08	2005-11-01	Fujisawa Pharmaceutical Co., Ltd.	Amyloid β protein agglutination-controlling factor
EP1208202A2 (en) *	1999-09-01	2002-05-29	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1637541B1 (en) *	1999-09-01	2010-03-03	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6337187B1 (en)	1999-11-05	2002-01-08	Millennium Pharmaceuticals, Inc.	18891, a novel human lipase
US20040248243A1 (en) *	2000-01-21	2004-12-09	Henry Yue	Lipid metabolism enzymes
AU2001232969A1 (en) *	2000-01-25	2001-08-07	Nuvelo, Inc.	Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
AU2001241412A1 (en) *	2000-01-31	2001-08-07	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
WO2001057262A1 (en) *	2000-02-03	2001-08-09	Hyseq, Inc.	Methods and materials relating to neuronal guidance molecule-like (ngm-like) polypeptides and polynucleotides
US7241585B2 (en)	2000-02-11	2007-07-10	Millennium Pharmaceuticals, Inc.	14171 protein kinase, a novel human protein kinase and uses thereof
US6630335B1 (en)	2000-02-11	2003-10-07	Millennium Pharmaceuticals, Inc.	14171 protein kinase, a novel human protein kinase and uses thereof
US6984519B2 (en) *	2000-03-01	2006-01-10	Genetech, Inc.	Nucleic acids encoding peptides that induce chondrocyte redifferentiation
WO2001074854A2 (en) *	2000-03-31	2001-10-11	Millennium Pharmaceuticals, Inc.	32449, a putative human transporter and uses thereof
EP1280915A1 (en) *	2000-04-13	2003-02-05	Millennium Pharmaceuticals, Inc.	23155 novel protein human 5-alpha reductases and uses therefor
WO2001081414A2 (en) *	2000-04-27	2001-11-01	Millennium Pharmaceuticals, Inc.	Integrin alpha subunit and uses thereof
WO2001090357A1 (en) *	2000-05-24	2001-11-29	Genesis Research & Development Corporation Limited	Compositions isolated from skin cells and methods for their use
CN1444652A (zh) *	2000-05-24	2003-09-24	先灵公司	哺乳动物受体蛋白;相关试剂和方法
EP2042597B1 (en) *	2000-06-23	2014-05-07	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20020064821A1 (en) *	2000-07-05	2002-05-30	Merkulov Gennady V.	Isolated human ion channel proteins, nucleic acid molecules encoding human ion channel proteins, and uses thereof
US20030120040A1 (en) *	2001-06-29	2003-06-26	Genentech, Inc.	Secreted and Transmembrane polypeptides and nucleic acids encoding the same
AU2003236351A1 (en) *	2002-04-03	2003-10-27	Banyu Pharmaceutical Co., Ltd.	Novel g protein-coupled receptor gene and protein bg8
EP1573034A4 (en)	2002-06-20	2006-06-14	Bristol Myers Squibb Co	IDENTIFICATION AND MODULATION OF A G PROTEIN-COUPLED RECEPTOR (GPCR), RAI3, ASSOCIATED WITH CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND REGULATION OF NF- $ G (K) B AND E-SELECTINE
JP2004135605A (ja) *	2002-10-18	2004-05-13	Nissui Pharm Co Ltd	脂肪細胞分化関連遺伝子およびタンパク質
AU2003277583A1 (en) *	2002-11-06	2004-06-07	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Physiologically active polypeptide and its antibody and use thereof
US7812116B2 (en) *	2003-07-03	2010-10-12	Rush University Medical Center	Immunogenic peptides
JP4789171B2 (ja) *	2004-03-16	2011-10-12	塩野義製薬株式会社	新規神経栄養因子
JP2006137747A (ja) *	2004-10-14	2006-06-01	Hayashibara Biochem Lab Inc	サイトカイン類及び／又はケモカイン類産生増強剤
WO2008096905A1 (ja) *	2007-02-09	2008-08-14	Tokyo Metropolitan Organization For Medical Research	抗ｂｒａｋ（ｃｘｃｌ１４）ヒトモノクローナル抗体及びその用途
WO2009021034A2 (en) *	2007-08-06	2009-02-12	University Of Rochester	Methods of treating b-cell cancers
DE102009010942A1 (de) *	2009-02-27	2010-09-02	Universitätsklinikum Schleswig-Holstein	Serinprotease-Inhibitoren zur spezifischen Inhibition von Gewebs-Kallikreinen
WO2011044721A1 (zh) *	2009-10-12	2011-04-21	复旦大学	Spink6基因及其编码蛋白在制备抗肿瘤药物中的应用
CN103088034A (zh) *	2011-10-30	2013-05-08	复旦大学	人spink6的基因优化及其在毕赤酵母中外分泌表达
US9345770B2 (en) *	2011-11-16	2016-05-24	University of Pittsburgh—of the Commonwealth System of Higher Education	Immunogenic tumor associated stromal cell antigen peptides and methods of their use
CN116712533B (zh) *	2023-07-03	2024-02-02	广东暨安特博生物科技有限公司	一种sostdc1蛋白在制备治疗皮肤病产品中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2153500A (en) *	1998-11-19	2000-06-05	Millennium Pharmaceuticals, Inc.	Egf-like nucleic acids and polypeptides and uses thereof

1999
- 1999-04-29 EP EP99922665A patent/EP1073740A4/en not_active Withdrawn
- 1999-04-29 WO PCT/NZ1999/000051 patent/WO1999055865A1/en not_active Application Discontinuation
- 1999-04-29 AU AU39614/99A patent/AU758074B2/en not_active Ceased
- 1999-04-29 JP JP2000546009A patent/JP2002512798A/ja active Pending
- 1999-04-29 CA CA002327317A patent/CA2327317A1/en not_active Abandoned
- 1999-04-29 CN CNB998080276A patent/CN1158386C/zh not_active Expired - Fee Related
- 1999-04-29 NZ NZ507728A patent/NZ507728A/en unknown

Also Published As

Publication number	Publication date
CN1158386C (zh)	2004-07-21
AU758074B2 (en)	2003-03-13
AU3961499A (en)	1999-11-16
WO1999055865A1 (en)	1999-11-04
EP1073740A4 (en)	2002-11-13
CN1307637A (zh)	2001-08-08
CA2327317A1 (en)	1999-11-04
JP2002512798A (ja)	2002-05-08
EP1073740A1 (en)	2001-02-07

Publication	Publication Date	Title
NZ507728A (en)	2002-06-28	Information from a cDNA library created from keratinocytes, dermal papilla, neonatal foreskin fibroblast or embryonic skin cells is used to treating cancer, angiogenesis, skin inflammation, inflammatory diseases or stimulating keratinocyte growth
WO2001090357A1 (en)	2001-11-29	Compositions isolated from skin cells and methods for their use
KR20010074494A (ko)	2001-08-04	피부세포에서 분리한 폴리뉴클레오티드와 이의 이용방법
US6380362B1 (en)	2002-04-30	Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
AU729880C (en)	2001-11-08	Recombinant vascular endothelial cell growth factor D (VEGF-D)
AU733322B2 (en)	2001-05-10	Novel VEGF-like factor
EP1185555A2 (en)	2002-03-13	Compositions isolated from skin cells and methods for their use
US20030022835A1 (en)	2003-01-30	Compositions isolated from skin cells and methods for their use
CA2133443A1 (en)	1993-10-14	Cloning, expression and uses of a novel secreted protein, f-spondin
US20030040471A1 (en)	2003-02-27	Compositions isolated from skin cells and methods for their use
EP1650221B1 (en)	2012-06-27	Novel compounds
US20030143676A1 (en)	2003-07-31	Fibroblast growth factor receptors and methods for their use
WO2000058463A1 (en)	2000-10-05	Polynucleotide and deduced amino acid sequences from stromal cells
JP2002541804A (ja)	2002-12-10	分泌ヒトタンパク質
KR100804885B1 (ko)	2008-02-20	경피증의 치료 또는 예방을 위한 ｓａｒｐ-1의 용도
CA2339418A1 (en)	2000-02-24	Human chordin-related proteins and polynucleotides encoding them
US7083791B2 (en)	2006-08-01	Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
KR20060106810A (ko)	2006-10-12	염증 및/또는 자가면역 질환에서 가용성 ｃｄ164의 용도
JP2003511069A (ja)	2003-03-25	甲状腺の過形成および腫瘍の核酸配列
AU779839B2 (en)	2005-02-17	Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof
AU2005244575B2 (en)	2008-06-05	Human Vascular Endothelial Growth Factor 2
KR20010030984A (ko)	2001-04-16	폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및이들의 용도
MXPA99003666A (en)	2000-04-24	Placental-derived prostate growth factors
CA2413012A1 (en)	1996-12-12	Human vascular endothelial growth factor 2

Legal Events

Date	Code	Title
2002-10-25	PSEA	Patent sealed
2003-05-30	RENW	Renewal (renewal fees accepted)
2006-05-26	RENW	Renewal (renewal fees accepted)